drugset / Trial / NCT02172378

12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales

NCT02172378

Phase 3 Completed 116 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Determine the effect of 12-week treatment with inhaled tiotropium bromide on lung function and static lung volumes, correlate this effect with dyspnoea in COPD patients.

Timeline

Start
2000-05
Primary completion
2002-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 18 ug Inhaled